TapImmune reports positive interim safety analysis in breast cancer study

Vaccine technologies company TapImmune has reported that positive interim safety analysis was achieved in breast cancer patients treated with HER2/neu antigens.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news